The Cross-Border Biotech Blog

CSRFeatImg

Welcome to your Canada in Science Review for July 17th, 2015! Nat Biotechnol. 2015 Jul 13. doi: 10.1038/nbt.3294. Directed differentiation of cholangiocytes from human pluripotent stem cells.   Proc Natl Acad Sci U S A. 2015 Jul 13. pii: 201502966. A multidrug resistance plasmid contains the molecular switch for type VI secretion in Acinetobacter baumannii.   J Allergy […]

read more


BBB_Part13_Logo

Market Exclusivity – Patents Market exclusivity is a critical component of valuation. Patenting strategies, regulatory data exclusivity and product life-cycle management will give about 10 to 15 years of market exclusivity to most novel drugs. The patent system originated during the industrial revolution – the first U.S. patent law was enacted in 1790. The concept […]

read more


Q2_2015_Part2(v2)_Feat_Img

Sideways with moderate volatility for Tier 2 companies   In this blog, I am going to comment on the Q2 and H1 performance of the Tier 2 group of 52 companies with share prices of between $0.10 and $0.99 to start 2015. Q2 2015 Tier 2 Performance  Decliners outnumbered advancers by 29 to 23  Average […]

read more


Financial_Times_Feat_Header(v2)

The public markets are getting closer to hearing about Bloom Burton & Co., a Toronto headquartered IIROC-registered broker-dealer that focuses on the healthcare sector. Click on the image above to read the full post.

read more


Q2_2015_Part2_Header_Img_Feat

Selective movement versus the herd mentality of Q1 For the 99 Canadian healthcare companies starting 2015 with share prices of $0.10 or higher, the decliners outnumbered advancers by 56 to 43 and the average share price change was -4.1% in Q2 2015. There were 6 companies with share price increases of 40% or more, whereas 9 […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for July 7th, 2015! Nat Chem. 2015 Jul;7(7):569-75. An electrochemical clamp assay for direct, rapid analysis of circulating nucleic acids in serum.   Mol Ther. 2015 Jun 30. doi: 10.1038/mt.2015.119. T cells engineered with chimeric antigen receptors targeting NKG2D ligands display lethal toxicity in mice.   PLoS Biol. 2015 Jun 30;13(6):e1002186. […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for July 6th, 2015! This week, QHR Corporation announced that one of its subsidiaries acquired the healthcare assets, proprietary software, and clients of Jonoke Software Development.  Meanwhile, the common shareholders of Resverlogix Corp. approved resolutions relating to a private placement of securities to Eastern Capital Limited for proceeds […]

read more


BBB_Part12_Logo

Some pharmaceutical industry history (1) The success rate for new drug development is low – about 10% of drugs which enter the clinic are approved. However, regulatory approval does not guarantee market success and only a few novel drug development companies have made, or are likely to make, the transition to top-tier, profitable and sustainable […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for June 22nd & 29th, 2015! In M&A news, Tribute Pharmaceuticals Canada Inc. kicked off the summer with the $25 million acquisition of Medical Futures, with Tribute concurrently raising $12.5 million in a private placement of secured subordinated debentures. In addition, M Pharmaceuticals completed the acquisition of Trimtec […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for June 19th, 2015! Cancer Cell. 2015 Jun 8;27(6):864-876. Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia.   Proc Natl Acad Sci U S A. 2015 Jun 8. pii: 201500857. TOE1 is an inhibitor of HIV-1 replication with cell-penetrating capability.   Nat Med. 2015 Jun […]

read more